Wellington Management Group LLP Sells 2,826 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Wellington Management Group LLP decreased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,500 shares of the specialty pharmaceutical company’s stock after selling 2,826 shares during the quarter. Wellington Management Group LLP’s holdings in Supernus Pharmaceuticals were worth $850,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. FMR LLC boosted its stake in Supernus Pharmaceuticals by 101.1% during the third quarter. FMR LLC now owns 16,903 shares of the specialty pharmaceutical company’s stock worth $527,000 after buying an additional 8,499 shares during the period. HighTower Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter worth about $264,000. Stifel Financial Corp boosted its stake in shares of Supernus Pharmaceuticals by 1.6% during the 3rd quarter. Stifel Financial Corp now owns 69,134 shares of the specialty pharmaceutical company’s stock worth $2,156,000 after purchasing an additional 1,093 shares during the period. Barclays PLC grew its holdings in Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares during the period.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,104 shares of company stock worth $440,263. Company insiders own 9.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on SUPN shares. StockNews.com lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, April 9th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $31.67 on Monday. The company has a market capitalization of $1.77 billion, a P/E ratio of 29.60 and a beta of 0.90. The company’s 50-day simple moving average is $33.52 and its two-hundred day simple moving average is $35.07. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.